You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ):2019年淨利預降5%-35%
格隆匯 01-20 16:34

格隆匯1月20日丨金城醫藥(300233.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤約1.72-2.51億元,同比下降5%—35%。業績變動原因如下:

1、報告期內,不考慮子公司北京金城泰爾製藥有限公司(“金城泰爾”)商譽減值,公司預計2019年實現歸屬於上市公司股東的淨利潤為4.24-5.4億元,與去年同期相比增長10%-40%。報告期內,公司主營業務經營情況良好,醫藥化工板塊市場保持穩定,生物特色原料藥、頭孢粉針製劑等產品銷售也較去年同期實現平穩增長。

2、報告期內,金城泰爾受行業政策、市場環境等因素影響,業績下滑。公司結合行業政策、市場環境等綜合性因素考慮,並根據審慎原則,對商譽進行了減值測試,認為金城泰爾存在減值跡象,預計計提商譽減值準備不超過2.9億元。具體計提金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。公司將在年報中詳細披露減值測試方法、測試過程等具體情況。

3、公司2019年度非經常性損益對淨利潤的影響金額在1.35-1.45億元之間。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account